签下185亿美元超级大单，石药为何反遭抛售？“聪明钱”悄然借道港股通创新药ETF（520880）埋伏

Core Insights - The strategic research and licensing agreement between CSPC Pharmaceutical Group and AstraZeneca marks a significant milestone in the outbound business development of Chinese innovative drugs, with a potential total value of up to $18.5 billion [1][3][12] - This transaction sets a new record for the highest total amount in business development deals for Chinese pharmaceutical companies, surpassing a previous deal valued at $13 billion [3][13] - Despite the positive news, CSPC's stock experienced a significant decline, dropping by 10.2% after initially opening higher, attributed to profit-taking by investors following a recent surge in stock price [1][15] Financial Details - The agreement includes an upfront payment of $1.2 billion, with the remaining $17.3 billion contingent on achieving various research and sales milestones over the coming years, indicating limited short-term cash flow contribution [3][15] - The overall market sentiment was affected by a broader decline in the Hong Kong stock market, with major indices falling over 2%, impacting the performance of other leading biotech companies [3][15] Market Dynamics - The current environment is seen as a favorable window for investing in core assets of innovative drugs, with analysts noting the convergence of drug pricing between China and the U.S. and a narrowing gap in market capitalization among innovative drug companies [5][17] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown resilience, with significant net subscriptions despite market volatility, indicating ongoing investor interest [16][18] Investment Tools - Investors are encouraged to consider high-elasticity T+0 instruments such as the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which offer unique advantages including 100% purity in innovative drug coverage and a high concentration of leading companies [7][19][20] - The ETF's structure aims to mitigate risks associated with less liquid stocks by enforcing weight reductions on such components, enhancing overall risk management [20]